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Abstract
Sepsis in human beings is a major problem involving many individuals and with a high death rate. Except for a single drug (recombi-
nant activated protein C) that has been approved for treatment of septic patients, supportive measures represent the main clinical
approach. There are many models of experimental sepsis, mostly in rodents. A commonly used model is cecal ligation and puncture
(CLP). In this model, robust activation of complement occurs together with up-regulation of C5a receptors (C5aR, C5L2) in a variety of
different organs (lungs, kidneys, liver, heart). In septic human beings there is abundant evidence for complement activation. Interception
of C5a or its receptors in the CLP model greatly improves survival in septic rodents. There is compelling evidence that CLP causes an
intense pro-inflammatory state and that C5a interaction with its receptors can be linked to apoptosis of the lymphoid system and cells
of the adrenal medulla, loss of innate immune functions of blood neutrophils, consumptive coagulopathy and cardiac dysfunction. These
findings may have implications for therapeutic interventions in human beings with sepsis.
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Introduction
Sepsis in human beings is a serious and often life-threatening situ-
ation that involves nearly 600,000 patients in North America, with a
death rate approaching 50% [1–6]. Besides supportive therapy
(fluid resuscitation, ventilatory support and related treatments) and
specific therapy (broad spectrum antibiotics), there is only one FDA-
approved drug: recombinant activated protein C (APC). APC causes
modest improvements in survival but has a central drawback. It is
an anti-coagulant that is used in the setting of sepsis, which per se
is associated with intrinsic coagulant changes (consumptive coag-
ulopathy). Accordingly, therapeutic use of APC carries with it poten-
tially life-threatening complications of haemorrhage and is a reason
for the strict limitations in its use in septic human beings.
Sepsis has been classified clinically as: sepsis, severe sepsis,
septic shock and multiorgan failure. There are, as yet, no specific
markers for sepsis, although plasma levels of interleukin (IL)-6 and
procalcitonin tend to correlate with the intensity of sepsis, but
these biomarkers are entirely non-specific biomarkers of sepsis.
Their plasma presence occurs after trauma and a variety of other
conditions. Clearly, we do not know enough about the fundamen-
tals of sepsis to adequately understand what is happening. Why is
sepsis occurring, and how can the progression to the more serious
stages of sepsis be stopped or reversed? In this review we will
focus chiefly on animal models of sepsis and what has been
learned from animal studies, mostly involving rodents. We will also
emphasize the role of the complement system in sepsis and the
fact the experimental sepsis converts a regulated inflammatory
response into a completely dysregulated inflammatory condition.
Models of sepsis
One of the early models of sepsis was vascular infusion of live
bacteria such as E. coli. In subhuman primates (monkeys,
baboons), vascular infusion of live E. coli results in complement
J. Cell. Mol. Med. Vol 13, No 10, 2009
4155© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
activation, hypotension, consumptive coagulopathy, fever, leuko-
cytosis followed by leucopoenia, and a variety of other signs and
symptoms which are known to develop during experimental and
human sepsis [7–10]. The model of vascular infusion of live bac-
teria has been criticized as having little relevance to human sepsis
because of the massive number of bacteria injected. In view of
recent PCR-based quantitation of bacterial DNA, this methodology
has suggested a far greater presence of bacteria in blood 
compared to the standard method of colony forming units (CFUs)
in blood. Accordingly, until the new methodology can be widely
compared to other methods for in vivo bacterial quantitation and
validated, it is premature to be definitive regarding the best
method to quantitate the bacterial burden in vivo. Another model of
sepsis is that of endotoxemia in which bacterial lipopolysaccharide
(LPS) (often from E. coli ) is injected intravenously or intraperi-
toneally, usually into rodents. It has recently been suggested that
this model is not a good surrogate for human sepsis for a variety
of reasons [11]. One of the more common models of sepsis is
cecal ligation and puncture (CLP) in rodents, which induces
polymicrobial sepsis (involving blood borne gram positive and
gram negative bacteria). The intensity of CLP-induced sepsis is
related to the area of cecum ligated, the number of punctures and
the size of the needle used for puncture. Because about 50% of
human beings develop sepsis associated with gram positive bac-
terial pneumonia [12, 13], there has been considerable contro-
versy about whether CLP animal model of sepsis as well as the
endotoxemic and infusion of live E. coli is relevant to what is
occurring in septic human beings. Another problem in this regard
is differences in rodent susceptibility compared to human suscep-
tibility to bacteria such as Staphylococcus aureaus. This organ-
isms is a major problem in bacterial pneumonia in human beings,
but mice tend to be highly resistant to the same organisms. Such
species differences in susceptibility imply that it may be difficult to
extrapolate data from mice to human beings, and vice versa.
Evidence for complement activation in sepsis
There is considerable evidence in both animal sepsis and human
sepsis that complement activation has occurred, as reflected by
consumptive depletion of complement and the appearance in
plasma of complement activation products (C3a, C4a, C5a ana-
phylatoxins) which are small peptides (circa 10 kD) with pro-
inflammatory activities, especially in the case of C5a. These small
peptides, collectively referred to anaphylatoxins, are present in
low concentrations but often have intense pro-inflammatory activ-
ities. C5a concentrations rarely exceed 10–100 nM in plasma from
septic human beings. C5a is highly reactive with C5a receptors
(C5aR, C5L2) on phagocytic cells (macrophages, neutrophils
[polymorphonuclear leucocytes – PMNs]) at very low concentra-
tions (1–10nM), inducing chemotaxis, enzyme release and a res-
piratory burst (with H2O2 production), all of which are features of
innate immune responses. When the levels of C5a are present
locally as in soft tissue, lung, joint spaces and in limited in
amounts, C5a tends to be protective, enhancing responses of res-
idential phagocytic cells or phagocytes that migrate into the area
in order to kill and clear bacteria. In the setting of sepsis, exces-
sive production of C5a resulting in detectable levels (e.g. 100 nM)
in plasma can lead to signalling paralysis in PMNs, preventing
activation of mitogen activated protein kinases (MAPKs) that are
required for chemotaxis, phagocytosis and the respiratory burst
[14]. Details of how excessive levels of C5a are highly harmful are
described below.
Sepsis as a dysfunctional inflammatory state
It has been known for some time that sepsis in human beings or
animals exhibits evidence suggesting that regulation of the inflam-
matory response has been lost, resulting in high levels of pro-
inflammatory mediators (IL-1, tumour necrosis factor [TNF]-,
IL-6, IL-8, etc.) in plasma. This has been referred to as the ‘sys-
temic inflammatory response syndrome’ (SIRS) [14]. The precise
reasons for the high blood levels of these inflammatory media-
tors are not understood and the extent to which these mediators
are responsible for multi-organ damage is still a matter of spec-
ulation. Over time during sepsis, there is often the presence of anti-
inflammatory mediators (e.g. IL-10, IL-12, IL-13), originally con-
sidered to be a response to the earlier appearing pro-inflammatory
mediators of SIRS. This situation was described by R. Bone to be
a ‘compensatory anti-inflammatory response syndrome’ (CARS)
[15]. Below, we will review evidence that sepsis causes major
changes in phagocytic cells and endothelial cells, leading to a pro-
inflammatory state that favours accumulation of PMNs in tissues
which may perhaps be related to attendant tissue and organ dam-
age during sepsis.
Protective effects of C5a generated 
in limited amounts
To put C5a into a biological perspective, if the amount of C5a 
generated locally (as at a site of bacterial infection) is limited 
(10 nM), remaining in the physiological range, there will be sev-
eral beneficial effects as described in Fig. 1. Interaction with C5aR
will lead to ‘priming’ of PMNs and macrophages, such that their
innate immune responses (respiratory burst, release of granule
enzymes, etc.) to a second agonist such as LPS are considerably
enhanced. C5a alone can also induce responses of phagocytic
cells, such as chemotactic migration, limited enzyme release and
translocation of cytosolic subunits of NADPH oxidase, which
results in assembly of a fully active oxidase on the cell membrane,
thereby allowing generation of O•2 and H2O2 within the phagocytic
vacuole and killing of ingested bacteria by HOCl, which is gener-
ated by the interaction of myeloperoxidase with its substrate, H2O2
C5a can also interact with endothelial cells, resulting in rapid
expression of P-selectin on the cell surface, paving the way for
intermittent adhesion (rolling) of PMNs on endothelial cells and
the eventual transmigration of PMNs (Fig. 1). C5a has two other
effects on endothelial cells: 1. Production of IL-8, the presence of
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which on endothelial cells can prime PMNs as they begin to
adhere to the endothelial surface; 2. A potentially dangerous effect
of C5a, induction of tissue factor expression on the endothelial cell
surfaces, setting the stage for intravascular coagulation [16–18].
It should be pointed out that there is a controversy related to the
ability of endothelial cells to express tissue factor in vivo, implying
the need for caution in assumptions of the in vivo expression of
the procoagulant molecule. Collectively, small, regulated amounts
of C5a results in enhanced innate immune functions of phagocytic
cells, while affecting endothelial cells in a way that initiates the
acute inflammatory cascade. Such responses of endothelial cells
to C5a may ‘prime’ adherent PMNs and assist in their adhesion to
the endothelium and subsequent transmigration into a site of bac-
terial infection. Excessive amounts of C5a can lead to loss of
innate immune functions of PMNs, which may lead to a cata-
strophic outcome (see below).
Sepsis-induced changes in signalling cascades
Sepsis triggers a cascade of alterations both in PMNs and
endothelial cells which results in conversion of these cells to a
pro-inflammatory state. In neutrophils, generation of limited
amounts of C5a activates phosphokinase C and cytosolic phos-
pholipase A2 which ultimately leads to phosphorylation of cytoso-
lic subunits of NADPH oxidase (p47phox, p67phox, p50phox) and oxi-
dase assembly and activation in the context of the phagocyte cell
membrane, resulting in H2O2 production and its conversion to
toxic oxygen products (e.g. hypochlorous acid), which can kill
bacteria. However, if excessive amounts of C5a are generated, this
can result in paralysis of MAPK pathways, resulting in signalling
paralysis and loss of bactericidal function of neutrophils (Fig. 2
and [14]). Limited amounts of C5a will also activate the PI3K and
Akt signalling pathways (Fig. 2), which results in events that
inhibit PMN apoptosis. The loss of PMN apoptosis in vivo is
thought to result in sustained presence of PMNs in blood and in
tissues, setting the stage for accentuated tissue injury [14]. Many
different mediators (C5a, IL-1, G-CSF [colony stimulating fac-
tor], etc.) have been shown to modify PMNs, such that they
become resistant to apoptosis [19, 20]. In CLP-induced sepsis, 
in vivo blockade of C5a greatly reduces the development of resist-
ance of blood PMNs to apoptosis [19]. In sepsis there is intense
activation of coagulation pathways (Fig. 2). As indicated, C5a can
induce expression of tissue factor on endothelial cells, triggering
intravascular coagulation and consumptive coagulopathy. During
sepsis blood PMNs become activated, with increased expression
of 2 integrins (CD11b/CD18), the process of which is C5a-
dependent [21]. Sepsis also causes expression of 1 integrin (as
measured by cell surface content of CD29, the common 1 inte-
grin unit) on surfaces of blood PMNs [21]. This integrin is not
ordinarily expressed on surfaces of blood PMNs. In addition, sepsis
leads to expression of the chemokine receptor on PMNs, CCR-2,
which reacts with MCP-1 (CCL-2), MCP-2 (CCL-4), MCP-3 (CCL-7)
and MCP-4 (CCL-12) (Fig. 3, [22]). Up-regulation of 1 and 2
integrins (the latter of which binds to ICAM-1 and iC3b) as well as
expression of CCR-2 implies that PMNs now have a ‘gain of 
function’, such that they can more robustly bind to ligands as well
as being able to respond to ligands that they usually do not
recognize. Collectively, blood PMNs and endothelial cells are con-
verted to a pro-inflammatory state during CLP-induced sepsis,
Fig. 1 Effects of physiological levels of C5a
(circa 10nM) on neutrophils, mono-
cytes/macrophages and endothelial cells.
The responses of the various cell types
result in enhanced innate immune
responses to infectious agents.
J. Cell. Mol. Med. Vol 13, No 10, 2009
4157© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
which may put tissues at risk of injury due to an intensified inflam-
matory response.
Divergent effects on phagocytic cells during sepsis
During CLP-induced sepsis in rats, excessive production of C5a
can lead to signalling paralysis of blood PMNs, resulting in loss of
protective innate immune functions [14]. Table 1 summarizes
studies in which blood PMNs, peripheral blood mononuclear cells
(PBMCs) and alveolar macrophages were isolated and compared
for functional responses before and after onset of sepsis (CLP). As
has been shown in many different studies of sepsis in animals and
in human beings, the innate immune responses of blood PMNs
were defective. Chemotaxis (to C5a and to a chemically unrelated
peptide, N-formyl Met Leu Phe) was defective, phagocytosis was
Fig. 2 Signalling pathway activation by C5a
on neutrophils, monocytes/macrophages
and endothelial cells, resulting in com-
promised innate immunity, resistance of
neutrophils to apoptosis, a cytokine
storm and disseminated intravascular
coagulation.
Fig. 3 Perturbations in blood neutrophils
during sepsis, resulting in the appear-
ance of high levels of CCR-2, which now
allows cells to respond to MCP-1 (CCR-2)
and related ligands. This represents a
‘gain of function’ for neutrophils.
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depressed and the respiratory burst (H2O2 production) was
impaired [14]. The last abnormality was due to a C5a-induced
defect in the ability of stimulated PMNs to translocate cytosolic
subunits (p47phox) of NADPH oxidase to the cell membrane where
full assembly and activation of the oxidase takes place [14]. The
effects on functional innate immune parameters in PBMCs and
alveolar macrophages remain to be determined.
When cytokine and chemokine production was assessed 
in vitro following in vitro incubation of leucocytes with LPS, medi-
ator production was suppressed in PMNs and PBMCs but
enhanced in alveolar macrophages [23]. Finally, in a similar man-
ner, LPS-induced activation (phosphorylation) of the MAPK,
ERK1/2, was depressed in blood PMNs but enhanced in lung
macrophages in the setting of CLP-induced sepsis. These data
suggest, in general, that there is a loss in function involving blood
PMNs and PBMCs and a gain in function in lung macrophages.
Either lung macrophages cannot be rendered functionally defec-
tive by exposure to C5a, or the amounts of C5a to which lung
macrophages are exposed after CLP is much lower than C5a lev-
els in blood, resulting in priming of lung macrophages. It is not
clear why there are such dramatic differences in functional
responses of phagocytic cells based on their location (vascular
versus extravascular) during sepsis.
Harmful effects of C5a and C5a receptors 
in experimental sepsis
As has been alluded to above, there are many harmful outcome
related to interaction of C5a with its receptors during sepsis. As
described above, considerable C5a is generated during sepsis and
appears within the vascular compartment, reaching plasma con-
centrations as high as 100 nM [24]. C5a receptors on PMNs and
in tissues are in a dynamic state after CLP. In general, mRNA and
protein for C5aR are up-regulated in a variety of organs (lung,
heart, kidney, liver) [25]. It appears that up-regulation of C5L2
also occurs, but not as robustly when compared to C5aR [25].
Figure 4 summarizes the results of C5a interacting with its recep-
tors after CLP. As described above, C5a binding with C5aR on
PMNs leads to MAPK signalling paralysis in these cells, resulting
in loss of innate immune functions. The outcome is loss of protec-
tive functions of PMNs and attendant lethal bacteraemia. The up-
regulation on blood PMN surfaces of CD18 indicates that these
cells have been activated. Increased expression of IL-6, IL-8, etc.
by endothelial cells implies that adherent PMNs will be activated
after contact with IL-6 and IL-8. C5a interaction with tissue
macrophages appears to be linked to development of the SIRS of
sepsis, due to priming of these cells and the resulting surge of
pro-inflammatory cytokines and chemokines in plasma and in tis-
sues. To what extent the presence of these mediators can be
directly linked to harmful events such as multi-organ damage and
failure is currently a matter of much debate. The interaction of
endothelial cells with C5a via interaction with C5aR results in a
pro-inflammatory state that can be linked to chemokine expres-
sion and induction of tissue factor, the latter contributing to dis-
seminated intravascular coagulation, consumptive coagulopathy
and formation of intravascular thrombi [16–18].
Development of immunosuppression during sepsis is well doc-
umented and has been assumed to be the result of apoptosis of
lymphoid cells (both T and B cells) and the ensuing development
of the immunosuppression of sepsis [26, 27]. Our own studies
have shown in CLP rats that the thymus undergoes massive apop-
tosis that is both C5a and C5aR dependent [28]. Within 3 hrs after
CLP, thymocytes bind higher amounts of C5a (due to increased
C5aR protein on surfaces of thymocytes) and can be shown to
undergo apoptosis in vitro after the addition of C5a [28].
Apoptosis is associated with engagement of the intrinsic (mito-
chondrial) apoptotic pathway featuring activation of caspases 3, 6
and 9. When anti-C5a is given at the time of CLP, caspase activa-
tion and apoptosis in thymocytes are greatly reduced [28]. There
is other evidence that the extrinsic pathway of apoptosis is also
engaged after CLP in mice, as defined by the requirements for Fas
and Fas ligand [29, 30].
We have recently shown that adrenal medullary cells also
undergo apoptosis during sepsis [31]. This would imply that the
major source of catecholamines (epinephrine and norepinephrine)
is lost during sepsis, compromising the ability to sustain adequate
blood pressure for tissue perfusion. During sepsis, it is well
described that the ‘cardiomyopathy of sepsis’ develops, which
refers to falling cardiac output, diminished blood pressure and
declining vascular perfusion (Fig. 4). Apoptosis of adrenal
medullary cells may lead to the loss of catecholamines, resulting
in the inability to maintain vascular tone. In human beings with
septic shock, restoration of blood pressure is accomplished by
infusion of vasopressors (to increase blood pressure) or positive
ionotropes (to increase cardiac output). There is evidence that the
Function PMNs PBMCs Macrophages
Phagocytosis, chemotaxis, respiratory burst (H2O2 production) Depressed Unknown Unknown
Cytokine, chemokine production (in vitro) Depressed Depressed Enhanced
MAPK (ERK1/2) activation in vitro Depressed Unknown Enhanced
Table 1 Functional changes in phagocytic cells during sepsis*
*PMNs, neutrophils; PBMCs, peripheral blood mononuclear cells.
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loss of adrenal medullary cells after CLP is linked to participation to
engagement of C5a receptors [31]. In addition to reductions in
plasma catecholamines during experimental sepsis, there are also
direct effects of C5a and C5aR on cardiomyocyte function. It has
been shown that sepsis causes increased levels of mRNA and
 protein for C5aR on cardiomyocytes [32]. Furthermore, cardiomy-
ocytes isolated from rat hearts after CLP show profound contractile
dysfunction, involving reduced contractility (sarcomere shortening)
and prolonged relaxation times [32]. If C5a is blocked at the begin-
ning of CLP, contractility function of cardiomyocytes and left
 ventricular pressures are essentially restored to normal values.
Furthermore, if sham or CLP cardiomyocytes are incubated in vitro
with recombinant C5a, a profound contractility defect develops in
these cells [32]. To what extent C5L2 may also be involved in the
acquisition of these defects is unknown at the present time.
In the literature there is evidence, at least in the endotoxemia
model in mice and in a model of burn injury, that cardiomyocyte
production of IL-6, Il-1 or TNF- may be linked to cardiac and
cardiomyocyte dysfunction [33]. Accordingly, these mediators
have been referred to ‘cardiosuppressive cytokines’. Precisely how
such observations might be related to ‘septic cardiomyopathy’ is
unknown at the present time.
Future directions
As indicated above, in both experimental sepsis and in human
beings with sepsis, there is compelling evidence for robust acti-
vation of complement. In sepsis following CLP in rodents, it
appears that C5a engagement with its receptors leads to a series
of events that: impair innate immune functions of blood PMNs;
trigger apoptosis of lymphoid cells as well as adrenal medullary
cells; initiate a generalized pro-inflammatory state; and lead to
development of septic cardiomyopathy which impairs vascular
perfusion. In rodents, the consequences of blockade of C5a,
C5aR or C5L2 are highly protective and greatly improve survival
after CLP suggesting that engagement of both C5aR and C5L2
lead to adverse outcome [34]. It is possible in human beings with
sepsis that such blocking interventions might be protective, with
C5a being the most obvious target using a humanized, neutraliz-
ing mAb to C5a that is unable to bind to C5 (which, when acti-
vated, generates C5a as well as the membrane attack complex
(C5b-9), the latter having lytic activity for gram negative bacte-
ria). Obviously, one broad concern is that a strategy aimed at
intercepting C5a in vivo might potentially compromise innate
immunity. However, one is talking about short term therapy
(days). It might also be pointed out that in C5 deficient human
beings the only clear problem is susceptibility to Neisserial infec-
tions. Critical issues include whether an intact IgG or an antibody
fragment should be used in the clinical setting of sepsis. The
problem with the antibody fragment is that its rapid clearance
from blood would bring about the need to infuse very large
amounts of antibody continuously over a 2–3 day period. Another
critical issue is patient selection. There has been only one suc-
cessful clinical trial in sepsis out of 40 or more failed clinical tri-
als (see ‘Introduction’). It is now clear that septic patients who
are the most ill are the most likely to benefit from such therapy,
implying that patient selection is absolutely key 
for the design of clinical trials. In several of the clinical trials, 
the 28-day lethality was around 30%, meaning that data from 
the majority of patients will likely dilute out data from a 
Fig. 4 Interaction of C5a with C5aR during sepsis, resulting in compromised innate immune functions of neutrophils, together with activation markers
and increased expression of pro-inflammatory mediators, coagulopathy, apoptosis of lymphoid cells, cardiomyopathy and apoptosis of adrenal
medullary cells.
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small cohort of patients who would benefit from the special 
intervention. As of yet, there are no specific biomarkers of 
sepsis, only biomarkers that indicate a pro-inflammatory state
that correlates with the severity of the clinical condition. Finally, it
is clear that we do not understand enough about the pathophysi-
ology of sepsis in order to intuitively move towards novel and
more effective therapies.
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